Press release

Siemens Healthineers invests €60 million in Kemnath production location

Expansion and upgrade of entire location by 2025

Published on 22. Februar 2022

  • Expansion and upgrade of entire location by 2025
  • Portfolio expanded to include Varian radiotherapy devices
  • 50 new jobs to be created

Siemens Healthineers will invest about €60 million through 2025 to expand and upgrade its location at Kemnath in Bavaria. The project will also create up to 50 new jobs. The investment will ensure that the strong demand for medical technology products can continue to be met with no impact on quality. Radiotherapy devices from Varian – linear accelerators – will also be manufactured at the location in the future. Siemens Healthineers will set up new production lines for that purpose and upgrade parts of the factory. In-house training at the location will be bolstered by the construction of a new workshop and the acquisition of new software and equipment. In addition, the energy systems in all buildings at the location will be upgraded. “Our traditional location in Kemnath will continue to play a key role for our business in the future,” says Michael Braunreuther, Head of the Kemnath location at Siemens Healthineers. “That’s why we’ll continue to invest in this area to support the future growth of the company and secure our leading position on the market. Our long-term plans for the future represent a clear commitment to the Kemnath location.”

The Kemnath plant in the Oberpfalz region was established in 1962. It has grown since then from a purely contract-based manufacturer to a Center of Competence for mechatronics that covers large parts of the Siemens Healthineers product range. The components developed and manufactured in Kemnath include C-arms for angiography systems in addition to tables for MRI units and components for analytical systems used in lab diagnostics. Siemens Healthineers currently employs a workforce of more than 1,200 at the location. It recently invested €13 million in a new logistics facility that began operations in January of this year.

Siemens Healthineers will construct a new administration building at the location for about 130 employees. It will include the new training workshop and the new reception area. The building should be able to be operated CO2-neutrally. To enable the manufacture of radiotherapy devices from Varian at Kemnath in the future, a completely new production line will be installed in the production area. Linear accelerators of this type are used in hospitals for the targeted treatment of cancer and are among the most technically innovative accelerator systems on the market. Delivery of the first systems is expected by as early as fall 2022. In addition to acquiring new processing machines, the existing 3D printing Center of Competence will be expanded to cover more space and more devices. This will enable individual metal or plastic components needed for production to be manufactured right on-site. A total of 50 new jobs will be created at the location, many in the areas of development and manufacturing.

Siemens Healthineers 2022

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at